Seniority 47 years , Professor ☺ 5 reviews $ Prices for treatments and diagnostics
✆ Make an appointment:
+74954812786
Dan Caspi
Doctor of the highest category, an expert rheumatologist. Head of rheumatological Ichilov Hospital Institute
Treat diseases
Dan Caspi - the head of the rheumatology department of Medical Center Ichilov-Sourasky in Israel. Professional interest in the country's A leading specialist focused on the study of the most complicated areas of medicine, namely rheumatology. During his medical practice Dr. continuously engaged in increasing hislevel of qualification, so that soon earned an excellent reputation and world fame. To carry out diagnostic procedures Dan Caspi uses only advanced and proven methodologies, and all the results of the diagnosis is confirmed by histological examination. it pays particular attention to the thorough study of the immune status of the patient, i.e. the search for autoantibodies that have a direct impact on the development of the disease.
Research Issues
1982-1984 Researcher, honored member of the department of Immunology, Royal School internship, Hammersmith hospital, London
Professional activities
- 2003 Chapter rheumatological Institute of Ichilov hospital, Tel-Aviv, Israel.
- 2000 Head of the day hospital in rheumatology department, Ichilov medical center - Sourasky
- 1985 One of the founders of rheumatology specialization programs in Israel
- 1979 specialist rheumatologist.
- 1973 Start of medical activity
Membership Community / Participation in events
- The Israeli Association of Rheumatology;.
- The American Association of Rheumatology.
scientific activities
engaged in a large number of research projects relating to the study of synovial cells, the potential capillaroscopy techniques, the use of biological therapy in autoimmune diseases.
The professor has more than 140 scientific publications and more than 100 presentations at scientific conferences behind him.
One of the most prominent publications
Professor, rheumatologist doctor Dan Caspi said the assessment of reliable effectiveness "Adalimumab" drug on the basis of monoclonal antibodies to be used for the treatment of patients with psoriatic arthritis. In comparison with conventional cytostatic, new drug showed significant improvement of the connective tissue in patients. Long-term studies were conducted with the help of ultrasound. http://www.ncbi.nlm.nih.gov/pubmed/25073614 Details of the treatment of arthritis in Israel https://docland.ru/israel/ortopedija/artrit
No questions asked
